ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR
14. März 2023 17:30 ET
|
ImCheck Therapeutics SAS
ImCheck To Present Data From the EVICTION-2 Study of ICT01 in Combination With IL-2 In Patients with Advanced Solid Tumors at AACR Marseille, France, March 14, 2023 – ImCheck Therapeutics...
ImCheck Publishes Comprehensive Overview of the Development Results of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cells in Science Translational Medicine
20. Oktober 2021 14:21 ET
|
ImCheck Therapeutics SAS
ImCheck Publishes Comprehensive Overview of the DevelopmentResults of Its First-in-class Cancer Immunotherapeutic Targeting BTN3A to Activate Vγ9Vδ2 T Cellsin Science Translational Medicine ...